Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation.
This study has evaluated whether candesartans prevent the recurrence of atrial fibrillation (AF) and decrease type III procollagen-N-peptide (PIIINP) levels. A total of 153 patients with AF were enrolled in this study. Three groups of patients were compared; candesartan group was treated with candesartan plus bepridil (n = 52); and carvedilol group with carvedilol plus bepridil (n = 51); and bepridil group with bepridil alone (n = 50). The primary end point was length of time to the recurrence of AF and all patients were ultimately followed-up for 730 days. Serum levels of the biomarkers were measured at baseline and after 24 months. Maintenance of sinus rhythm was achieved in 25 (50%) patients in bepridil group, 37 (73%) in candesartan group, and 34 (67%) in carvedilol group, giving a bepridil group/candesartan group hazard ratio of 0.36 (95% confidence interval 0.21-0.63; P = 0.03). Candesartan significantly decreased PIIINP levels at 24 months than at baseline in sinus rhythm group (0.57 +/- 0.02 vs. 0.64 +/- 0.05 U/mL, P = 0.04) and did not decrease PIIINP levels in the recurrence group. In conclusions, PIIINP might be related to the possibility of the atrial fibrosis for AF. However, further studies are needed to clarify the relationship between PIIINP and AF.
Kawamura
Mitsuharu
M
Division of Cardiology, Showa University School of Medicine, Tokyo, Japan. mitsuhitoharu@yahoo.co.jp
Ito
Hiroyuki
H
Onuki
Tatsuya
T
Miyoshi
Fumito
F
Watanabe
Norikazu
N
Asano
Taku
T
Tanno
Kaoru
K
Kobayashi
Youichi
Y
D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D015764:Bepridil / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood*; D001713:Biphenyl Compounds; D002097:C-Reactive Protein / Q000032:analysis; D004359:Drug Therapy, Combination; D015716:Electrocardiography, Ambulatory; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D053208:Kaplan-Meier Estimate; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010446:Peptide Fragments / Q000097:blood*; D011347:Procollagen / Q000097:blood*; D011446:Prospective Studies; D013777:Tetrazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D001562:Benzimidazoles; D015415:Biomarkers; D001713:Biphenyl Compounds; D015850:Interleukin-6; D010446:Peptide Fragments; D011347:Procollagen; D013777:Tetrazoles; C041876:procollagen Type III-N-terminal peptide; D020097:Natriuretic Peptide, Brain; D015764:Bepridil; D002097:C-Reactive Protein; C081643:candesartan